LAP15 Rec'd PCT/PTO 22 SEP 2006

FORM PTO-1390 (Modified)
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE
(REV 12-2004)

_		6								
		ANSMITTAL LETTER TO THE UNITED STATES	ATTORNEY'S DOCKET NUMBER							
		ESIGNATED/ELECTED OFFICE (DO/EO/US)	084437-0169							
	С	ONCERNING A FILING UNDER 35 U.S.C. 371	U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/584,242							
		DNAL APPLICATION NO. INTERNATIONAL FILING DATE 12/24/2004	PRIORITY DATE CLAIMED 12/25/2003							
		VENTION								
		OF IMPROVING SUITABILITY FOR GRANULATION (S) FOR DO/EO/US								
	Yusuke N	MURAKAWA et al.								
Ι		rewith submits to the United States Designated/Elected Office (DO/EO/U	· -							
1.		This is a FIRST submission of items concerning a filing under 35 U.S.C	:. 371.							
2.	\boxtimes	This is a SECOND or SUBSEQUENT submission of items concerning	a filing under 35 U.S.C. 371.							
3.		This is an express request to begin national examination procedures (3 items (5) , (6) , (9) and (21) indicated below.	5 U.S.C. 371(f)). The submission must include							
4.		The US has been elected (Article 31).								
5.		A copy of the International Application as filed (35 U.S.C. 371(c)(2))								
ŀ		is attached hereto (required only if not communicated by the Inte	ernational Bureau).							
		has been communicated by the International Bureau.								
		is not required, as the application was filed in the United States	Receiving Office (RO/US)							
6.		An English language translation of the International Application as filed	(35 U.S.C. 371(c)(2)).							
		is attached hereto.								
	_	has been previously submitted under 35 U.S.C. 154(d)(4).								
7.		Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not transmitted by the International Bureau). have been communicated by the International Bureau have not been made; however, the time limit for making such amendments has NOT expired.								
		have not been made and will not be made.								
8.		An English language translation of the amendments to the claims under ${}^{^{^{1}}}_{^{^{1}}}$	r PCT Article 19 (35 U.S.C. 371(c)(3)).							
9.		An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).								
10.		An English language translation of the annexes to the International Pre 36 (35 U.S.C. 371(c)(5)).	liminary Examination Report under PCT Article							
lter	ns 11 to	20 below concern other document(s) or information included:								
11.	\boxtimes	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.								
12.		An assignment document for recording. A separate cover sheet in con	appliance with 37 CFR 3.28 and 3.31 is included.							
13.		A preliminary amendment.								
14.		An Application Data Sheet under 37 CFR 1.76.								
15.		A substitute specification.								
16.		A power of attorney and/or change of address letter.								
17.		A computer-readable form of the sequence listing in accordance with Pe	CT Rule 13ter.2 and 37 CFR 1.821 – 1.825							
18.		A second copy of the published international application under 35 U.S.C	C. 154(d)(4).							
19.		A second copy of the English language translation of the international a	pplication under 35 U.S.C. 154(d)(4).							
20.		Other items or information:								

WASH_1691584.1

U.S. APPLICATION NO. (If known, a 10/584,242	ico 37 CFR. (1.5)		75 DOCH 87-016	ET NUMBER 9					
The following fe	es have been su								
21. A Basic national			\$3	300	\$	300.00			
22. Examination fe If International preliminary provisions of PCT Articl All other situations	examination rep	s satisfy 100 200	\$	200.00					
		n paid on the international							
USPTO as an Internation	nal Searching A	Authority		100	1				
International Search Repo	rt prepared and	provided to the Office	\$4	100					
All other situations			\$5	500	\$	400.00			
TOTAL	OF ABOVE 21,	22 and 23 =			\$	900.00			
sequence listing or or	omputer prograr al 50 sheets of p	rawings filed in paper over 1 m listing filed in an electronic paper or fraction thereof.	c medium). The fee					
Total Sheets Extra shee	ets Numb thereo	er of each additional 50 or f f (round up to a whole num	raction ber)	RATE					
	/50 =	0		x \$250.00	\$	0.00			
earliest claimed priority da	te (37 CFR 1.49				\$	0.00			
CLAIMS N	UMBER FILED	NUMBER EXTRA		ATE	\$				
Total Claims 17	- 20 =	0	x\$	50.00	\$	0.00			
Independent Claims 4	-3=	1	x\$	200.00	\$	200.00			
MULTIPLE DEPENDENT	CLAIM(S) (if ap	plicable)	+\$	360.00	\$				
		TOTAL OF ABOV	E CALCU	LATIONS =	\$	1100.00	·		
Applicant claims s reduced by 1/2.	mall entity statu	s. See 37 CFR 1.27. Fees	above are	+	\$	0.00			
			SI	JBTOTAL =	\$	1100.00			
Processing fee of 130.00 t from the earliest claimed p		English translation later th CFR 1,492(i)).	an 30 moi	nths	\$				
	· · ·		AL NATIO	NAL FEE =	\$	1100.00			
		nt (37 CFR 1.21(h)). The as			\$				
accompanies by an appro	priore cover site	TOTAL FEES P			s	1100.00			
					_	mount to be refunded:			
						charged:			
a. A check in the	e amount of	to cover the above	fees is e	nclosed.	I		1		
		Account No. <u>19-0741</u> in a et is enclosed.	the amou	ınt of	to cov	er the above f	ees.		
c. The Commiss overpayment	sioner Is herel to Deposit Ac	by authorized to charge count No. <u>19-0741</u> . A di	any add uplicate d	itional fees copy of this	which sheet i	may be requir s enclosed.	red, or credit any		
d. Fees are to be charge to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.									
NOTE: Where an ap	propriate tim be filed and g	e limit under 37 CFR ranted to restore the In	1.495 ha	s not beer nal Applica	met,	a petition to pending sta	revive (37 CFR tus.		
SEND ALL CORRESP	ONDENCE TO	D:		-/	typh	Blan			
Foley & Lard	inor LLD			SIGNATU					
		0		Stephen	B. Ma	edius			
Customer N	umber: 2242	0		NAME					
				35,264					
				REGISTE	OITAS	N NUMBER			

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Yusuke MURAKAWA et al.

Title: METHOD OF IMPROVING SUITABILITY

FOR GRANULATION

Appl. No.: 10/584,242

International 12/24/2004

Filing Date:

371(c) Date: 6/23/06

Examiner: Unassigned

Art Unit: Unassigned

Conf. No.: 1685

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to

Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

English abstracts are now provided for JP 2001-335469 and JP 2003-160474, both previously cited. An English abstract is on the first page of WO 02/078673.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date SEP 2 2 7006

FOLEY & LARDNER LLP Customer Number: 22428 Telephone: (202) 672-5569

Facsimile: (202) 672-5399

Stephen B. Maebius Attorney for Applicant Registration No. 35,264

Auto BMak

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control
number.

u <u>mber.</u>						
	Substitute for form	1449B	/PTO	Complete if Known		
	INFORMATION D	SCLO	SURE	Application Number	10/584,242	
	STATEMENT BY		CANT	Filing Date	12/24/2004	
_	ate Submitted: St	TP 2	2 2006	First Named Inventor	Yusuke MURAKAWA	
U	ate Submitted:		- 2000	Group Art Unit	Unassigned	
	(use as many sheets	as ne	cessary)	Examiner Name	Unassigned	
Sheet	1	of	1	Attorney Docket Number	084437-0169	

U.S. PATENT DOCUMENTS								
Examiner Initials*		U.S. Patent	Document	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	Cite No.1	Number	Kind Code ² (if known)					
			-					

				F	OREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No.1	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁰	
	B1	JP	2001-335469	Α	Lion Corp.	12/04/2001		Α
	B2	JP	2003-160474	A	Taisho Pharmaceut Co Ltd	06/03/2003		Α
	B3	wo	99/47125	A1	Andrx Pharmaceuticals Inc	09/23/1999		Τ
	B4	WO	02/078673	A1	Takeda Chemical	10/10/2002		Α
					Industries, Ltd.			

NON PATENT LITERATURE DOCUMENTS									
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	т'						
	B5	LERK et al., "Application of sucrose laurate, a new pharmaceutical excipient, in peroral formulations of cyclosporin A," International Journal of Pharmaceutics, vol. 92, 1993, pp. 197-202.							
	В6	RUDDY et al., "Design and characterization of a surfactant-enriched tablet formulation for oral delivery of a poorly water-soluble immunosuppressive agent," International Journal of Pharmaceutics, vol. 182, 1999, pp. 173-186.							

				$\overline{}$
Examiner Signature	/Paul Dickinson/	Date Cons	04/01/2008 sidered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{*} Unique, citation designation number, *See attached Kinds of U.S. Patent Documents. *Fater Office that issued the document by the two-letter code (WIPO) Standard ST3. *Jor Aspanses patent documents, the indication of the year of the regin of the Emporer must precede patent document. *Inclined document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, *Applicant is to place a check mark here if English Insurance Translation is attached.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Other Information Officer, U.S. Patent and Tandeman's ON. Box 1450, Alexandria, VA. 22319-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA. 22319-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA. 22319-1450.